Table 1.

Summary of clinical feature of patients with PV treated with idasanutlin with TP53 mutant clones

Patient	Age, y	Sex	Time on study, wk	No. of TP53 mutations	Clinical response	Prior therapy
1	68	Female	105.1	1	PR	HU, IFN
2	48	Male	85.1	5	PR	IFN
3	52	Female	90.9	1	CR	HU
4	65	Male	70.1	3	CR	HU
5	83	Female	37.1	2	NR	HU

Clinical responses were assessed by using European LeukemiaNet criteria.

CR, complete response; HU, hydroxyurea; IFN, interferon; NR, no response; PR, partial response.